Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD
Authors:
- Pauliina MolanderPMPauliina Molander
- Taina SipponenTSTaina Sipponen
- Helena KemppainenHKHelena Kemppainen
- Airi JussilaAJAiri Jussila
- Timo BlomsterTBTimo Blomster
- Ritva KoskelaRKRitva Koskela
- Markku NissinenMNMarkku Nissinen
- Henna RautiainenHRHenna Rautiainen
- Juha KuismaJKJuha Kuisma
- Kaija-Leena KolhoKKKaija-Leena Kolho
- Martti FärkkiläMFMartti Färkkilä
Open Access
- 1 October 2013
- journal article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 7 (9) , 730-735
Abstract
Deep remission, meaning clinical remission with mucosal healing (MH), with anti-tumor necrosis factor-alpha (TNF-α) agents is a new target for therapy in inflammatory bowel disease (IBD). Our aim was to study how often patients on TNF-α blocking therapy actually achieve deep remission. The total of 252 IBD patients retrospectively included (183 Crohn's disease (CD), 62 ulcerative colitis (CU) or 7 inflammatory bowel disease unclassified-type colitis (IBDU)) received TNFα-antagonists (177 infliximab, 75 adalimumab) for at least 11 months and underwent ileocolonoscopy. We reviewed endoscopic and histological findings, clinical symptoms, C-reactive protein (CRP), and fecal calprotectin (FC) levels, and data on TNF-α blocking therapy. Defining deep remission as no clinical symptoms with endoscopic remission (the simple endoscopic score for Crohn's disease, SES-CD 0-2 or Mayo endoscopic subscore 0-1). Of the 252 patients, 168 (67%) were in clinical remission and 122 (48%) in deep remission after a median of 23 months of maintenance therapy. Of the 183 CD patients, 117 (64%) reached clinical remission and 79 (43%) deep remission. Of the UC patients, 52 (75%) were in clinical remission and 43 (62%) in deep remission. The majority of patients in deep remission (n=99, 81%) also had histologically inactive disease. Both median CRP and FC levels were significantly lower in patients with deep remission. Reassuringly, half of the IBD patients on the TNFα-blocking maintenance therapy achieved deep remission. The majority of patients in deep remission also achieved histological remission.Keywords
This publication has 31 references indexed in Scilit:
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative ColitisGastroenterology, 2012
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative ColitisGastroenterology, 2011
- Guidelines for the management of inflammatory bowel disease in adultsGut, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based CohortGastroenterology, 2007
- Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?Gut, 2007
- Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's diseaseGastrointestinal Endoscopy, 2006
- Infliximab for Induction and Maintenance Therapy for Ulcerative ColitisNew England Journal of Medicine, 2005
- Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology, 2004
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987